New York University · BiologyThe Microbiome Immunotherapy Nexus
Dan Littman · New York, New York
Research Focus
Dr. Dan Littman's lab at NYU School of Medicine focuses on how the gut microbiome influences the effectiveness of immunotherapy in lung cancer. By studying specific bacterial species and their products, the lab aims to uncover mechanisms that enhance immune responses against tumors, potentially leading to better treatment outcomes for patients. This research could help identify which patients may benefit most from immunotherapy and reduce harmful side effects.
microbiomeimmunotherapylung cancercheckpoint blockadeautoimmunity
Research Aims
5AIM 01Identify bacterial species that enhance anti-tumor immune responses in lung cancer.
AIM 02Characterize the host pathways affected by these beneficial microbes.
AIM 03Assess the immune effects of candidate microbes in tumor models.
AIM 04Evaluate metabolites associated with therapeutic response in lung cancer patients.
AIM 05Investigate the connections between microbiota and tumor antigen specificity.
Skills the Lab Values
cell culturemouse modelsPCRmetagenomicsspatial transcriptomicsflow cytometryproteomicsgenetic engineeringbacterial library screening
Output against the department
Publications501top 8% of dept.83rd of 1,033
this lab
most publishedleast published
Citations130ktop 1% of dept.7th of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.